Literature DB >> 7948100

Functionalized derivatives of hyaluronic acid oligosaccharides: drug carriers and novel biomaterials.

T Pouyani1, G D Prestwich.   

Abstract

Oligosaccharides derived from hyaluronic acid (HA), a naturally occurring linear polysaccharide composed of repeating disaccharide units of N-acetyl-D-glucosamine and D-glucuronic acid, can be chemically modified to introduce a pendant amine-like functionality (patent application pending). Covalent attachment of steroidal and nonsteroidal antiinflammatory drugs to functionalized HA oligosaccharides was accomplished with the incorporation of hydrolytically labile bonds. Further derivatization of the pendant group with homobifunctional crosslinkers allowed the introduction of covalent crosslinks. Chemically-modified HA oligosaccharides were unambiguously characterized in solution by high-resolution 1H NMR spectroscopy.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7948100     DOI： 10.1021/bc00028a010

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN： 1043-1802            Impact factor:   4.774


  32 in total

1.  Tunable CD44-specific cellular retargeting with hyaluronic acid nanoshells.

Authors:  Morten F Ebbesen; Morten Tj Olesen; Mikkel C Gjelstrup; Malgorzata M Pakula; Esben Ku Larsen; Irene M Hansen; Pernille L Hansen; Jan Mollenhauer; Birgitte M Malle; Kenneth A Howard
Journal:  Pharm Res       Date:  2014-11-01       Impact factor: 4.200

2.  Molecular basis for the explanation of the exponential growth of polyelectrolyte multilayers.

Authors:  C Picart; J Mutterer; L Richert; Y Luo; G D Prestwich; P Schaaf; J-C Voegel; P Lavalle
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-17       Impact factor: 11.205

3.  Development of multifunctional hyaluronan-coated nanoparticles for imaging and drug delivery to cancer cells.

Authors:  Mohammad H El-Dakdouki; David C Zhu; Kheireddine El-Boubbou; Medha Kamat; Jianjun Chen; Wei Li; Xuefei Huang
Journal:  Biomacromolecules       Date:  2012-03-13       Impact factor: 6.988

4.  Molecular weight and concentration of heparin in hyaluronic acid-based matrices modulates growth factor retention kinetics and stem cell fate.

Authors:  Amit K Jha; Anurag Mathur; Felicia L Svedlund; Jianqin Ye; Yerem Yeghiazarians; Kevin E Healy
Journal:  J Control Release       Date:  2015-04-27       Impact factor: 9.776

5.  Mechanistic Insight into Receptor-Mediated Delivery of Cationic-β-Cyclodextrin:Hyaluronic Acid-Adamantamethamidyl Host:Guest pDNA Nanoparticles to CD44(+) Cells.

Authors:  Vivek Badwaik; Linjia Liu; Dinara Gunasekera; Aditya Kulkarni; David H Thompson
Journal:  Mol Pharm       Date:  2016-02-22       Impact factor: 4.939

Review 6.  Hyaluronan-CD44 interactions as potential targets for cancer therapy.

Authors:  Suniti Misra; Paraskevi Heldin; Vincent C Hascall; Nikos K Karamanos; Spyros S Skandalis; Roger R Markwald; Shibnath Ghatak
Journal:  FEBS J       Date:  2011-03-25       Impact factor: 5.542

7.  Hyaluronic acid based materials for intestine tissue engineering: a morphological and biochemical study of cell-material interaction.

Authors:  A Esposito; A Mezzogiorno; A Sannino; A De Rosa; D Menditti; V Esposito; L Ambrosio
Journal:  J Mater Sci Mater Med       Date:  2006-12       Impact factor: 3.896

8.  Cell-Mediated Dexamethasone Release from Semi-IPNs Stimulates Osteogenic Differentiation of Encapsulated Mesenchymal Stem Cells.

Authors:  Sooneon Bae; Ho-Joon Lee; Jeoung Soo Lee; Ken Webb
Journal:  Biomacromolecules       Date:  2015-08-17       Impact factor: 6.988

9.  Intratumoral delivery of Paclitaxel in solid tumor from biodegradable hyaluronan nanoparticle formulations.

Authors:  Abeer M Al-Ghananeem; Ahmad H Malkawi; Yahya M Muammer; Justin M Balko; Esther P Black; Walid Mourad; Edward Romond
Journal:  AAPS PharmSciTech       Date:  2009-04-21       Impact factor: 3.246

Review 10.  Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor.

Authors:  Virginia M Platt; Francis C Szoka
Journal:  Mol Pharm       Date:  2008-06-03       Impact factor: 4.939
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.